Skip to content
Science

Mar 22, 2021

Mass Dynamics 1.0 paper on BioRxiv

Over the past 20 years, Mass Spectrometry (MS) and Bioinformatics have driven rapid increases in both the sensitivity and quantity of detection of proteins. The invention of not only high throughput, but low cost protocols is rapidly creating possibilities for biologists and specialists in Proteomic MS.

Bass Dynamics 1.0 BioRxiv

We are proud to showcase Mass Dynamics' first paper that has been submitted to pre-print server, BioRxiv. You can read the full paper here (https://www.biorxiv.org/content/10.1101/2021.03.03.433806v1).

A summary of the MD 1.0 paper

Over the past 20 years, Mass Spectrometry (MS) and Bioinformatics have driven rapid increases in both the sensitivity and quantity of detection of proteins. The invention of not only high throughput, but low cost protocols is rapidly creating possibilities for biologists and specialists in Proteomic MS. However, this is placing a burden on proteomics experts to facilitate and educate the broader community attempting to leverage these tools. 

Mass Dynamics (MD) 1.0, is the first iteration of a platform designed not only to scale with the computational demands of 21st century MS, but to facilitate and safeguard the interactions between collaborators making use of these tools from a wide range of backgrounds. 

While many other challenges and opportunities are critical for the long term success of MS in enabling us to understand biology and cure disease, we believe that engineering MS tools for accessibility and true scalability is likewise an important task.

MD 1.0 provides a novel combination of features, aimed at ensuring experimental validity whilst magnifying ease-of-use and throughput and until now, as far as we know, cloud storage of experiments and simple link-type sharing of experimental analysis has not yet been developed among tools facilitating proteomic analysis. 

You can get started today by signing up to a free membership.

We hope you enjoy the paper, and welcome all feedback. Happy discovering!

Dora is our good news megaphone. She draws on decades of marketing and commercial experience across many diverse sectors to help uplift and grow the entire mass spectrometry community.

Latest Articles

Thoughts

Transforming Drug Discovery: The Critical Role of Proteomics and Targeted Protein Degradation in the Future of Therapeutics

Dr. Andrew I Webb explores how advanced proteomics and Targeted Protein Degradation (TPD) are revolutionizing drug discovery, unlocking new...

October 15, 2024

Thoughts

Coffees, conversations, and negotiations: an energizing day @ FeMS “Out Of The Shadows” Workshop

How we learnt to increase executive presence, harness the power of story telling and gain confidence presenting beyond the lab

August 28, 2024

Thoughts

ASMS 2024: The rise of Automation and AI-Driven Raw MS Data Processing Solutions

72nd Conference on Mass Spectrometry and Allied Topics. Anaheim Conference Center, Anaheim, CA. 2nd-6th June, 2024

June 19, 2024